| Presentation preference | Oral presentation |
| Title | Real-life experience of Fluocinolone Acetonide Implant (Iluvien®) in non-infectious uveitic macular edema |
| Purpose | To evaluate the efficacy and safety of the Fluocinolone Acetonide (FAc, Iluvien) implant in uveitic macular edema (UME). |
| Methods | Retrospective, multicenter (France) real-life study including patients with UME and having received at least 1 FAc injection. |
| Results | 26 eyes of 23 patients (mean age:60+/-16 years) were included with a mean follow-up of 10.4+/-6.6 months. Uveitis was anterior, intermediate, posterior/panuveitis in 0%,12% and 88% of cases. All eyes received at least 1 Dexamethasone injection (DEXi) prior to FAc with an average of 1.5 DEXi/year. Before FAc, 27% of patients were on oral steroids and 27% on immunosuppressants. 25 eyes were pseudophakic. The mean best corrected visual acuity (BCVA) was 0.43+/-0.36 LogMAR at baseline increasing to 0.32+/-0.45 at 1 month (M1), 0.21+/-0.27 at M3, 0.21+/-0.27 at M6 and 0.31+/-0.31 at M12 (all p<0.05).The mean baseline central macular thickness (CMT) was 400+/-110µm decreasing to 307+/-65 at M1, 313+/-94 at M3, 329+/-94 at M6 and 307+/-53µm at M12 (all p<0.05). UME was absent in 84%, 84%, 78% and 64% at M1, 3, 6 and 12. Four eyes experienced a relapse of UME (5+/-2.4 months after FAc) requiring a new DEXi. The mean number of DEXi decreased to 0.20/year after FAc. At the last follow-up, 42% of patients had reduced their dose of oral steroids. No immunosuppressive treatment could be stopped. Five eyes (19%) showed ocular hypertension requiring anti-glaucoma drops (but no surgery). One eye was transiently hypotonic. No other adverse events were noted. |
| Conclusion | The FAc implant led to a significant improvement in BCVA and CMT up to 12 months. The majority of adverse events were mild and controlled by medical treatment. |
| Conflict of interest | No |
Authors 1
| Last name | TOUHAMI |
| Initials of first name(s) | S |
| Department | Ophthalmology |
| City | Paris |
| Country | France |
Authors 2
| Last name | Jabbour |
| Initials of first name(s) | M |
| Department | Ophthalmology |
| City | Paris |
| Country | France |
Authors 3
| Last name | Rougier |
| Initials of first name(s) | MB |
| Department | Ophthalmology |
| City | Bordeaux |
| Country | France |
Authors 4
| Last name | Serrar |
| Initials of first name(s) | Y |
| Department | Ophthalmology |
| City | Lyon |
| Country | France |
Authors 5
| Last name | Kodjikian |
| Initials of first name(s) | L |
| Department | Ophthalmology |
| City | Lyon |
| Country | France |
Authors 6
| Last name | Mazhar |
| Initials of first name(s) | D |
| Department | Ophthalmology |
| City | Nantes |
| Country | France |
Authors 7
| Last name | Weber |
| Initials of first name(s) | M |
| Department | Ophthalmology |
| City | Nantes |
| Country | France |
Authors 8
| Last name | Perez-Roustit |
| Initials of first name(s) | S |
| Department | Ophthalmology |
| City | Grenoble |
| Country | France |
Authors 9
| Last name | Chiquet |
| Initials of first name(s) | C |
| Department | Ophthalmology |
| City | Grenoble |
| Country | France |
Authors 10
| Last name | Bodaghi |
| Initials of first name(s) | B |
| Department | Ophthalmology |
| City | Paris |
| Country | France |
